Murine IFN gamma ELISpot Kit

Datasheet

Catalog Number: 862.031.001PC

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Key Features

Species Reactivity :

Murine

Application :

ELISpot

SKU Price(USD) Size Qty

862031001PC_1 x 96 Discovery (pre-coated plate) $361.96 1 x 96 Discovery (pre-coated plate)

Qty:

+ -

Custom Quote

Bulk or bespoke? We IVDo that
Request a call back
to discuss your information requirements

Key Documents

Murine IFNγ ELISpot Kit – Pre-coated - Instructions for use

Product Overview

Product Name	Murine IFN gamma ELISpot Kit
Catalog Number	862.031.001PC
Description	Diaclone Pre-coated ELISpot kits include precoated PVDF plates, Detection antibody, Alkaline phosphatase conjugate, BSA, BCIP/NBT ready-to-use substrate buffer.
Application	ELISpot
Alternative Names	(click to expand) IFN-g, IFN-gamma

Further Specification

Cross Reactivity	No cross reactivity with other murine cytokines
Specificity	Recognizes natural murine IFN-g

Storage and Shipping

Storage	Store at +4°C
Shipping	Room temperature

References

PubMed	Huang, J. et al., Vaccine. 2006 Jun 5; 24(23): 4905–4913. - Pubmed link Van Hoecke, L. et al., Oncoimmunology. 2020; 9(1): 1802968. - Pubmed link Van Hoecke, L. et al., Mol Ther Nucleic Acids. 2020 Dec 4; 22: 373–381. - Pubmed link Hofer, T. et al., Cancers (Basel) 2021 Dec; 13(23): 6107. - Pubmed link Ramakrishna L. et al., J. Virol., 2004; 78(17): 9174 - 9189 - Pubmed link Someya K. et al., J. Virol., 2004; 78(18): 9842 - 9853 - Pubmed link Tsunoda, I. et al., J Virol.,2005; 79(23): 14640-6. - Pubmed link Yan, L. et al., Infect. Immun.,2008; IAI.00245-08. - Pubmed link Musson, J. A. et al., Infect. Immun.,2010; (78): 4356-4362 - Pubmed link Pollard, C. et al., Mol Ther..,2013; 21(1): 251-9 - Pubmed link Patil, H.P. et al.,Vaccines (Basel). 2017 Jul 27;5(3). pii: E19. - Pubmed link Van Hoecke L et al., Nat Commun. 2018 Aug 24;9(1):3417 - Pubmed link Joe, P.T. et al., J Transl Med. 2019 Jul 25;17(1):242. - Pubmed link

PubMed

Huang, J. et al., Vaccine. 2006 Jun 5; 24(23): 4905–4913. - Pubmed link
Van Hoecke, L. et al., Oncoimmunology. 2020; 9(1): 1802968. - Pubmed link
Van Hoecke, L. et al., Mol Ther Nucleic Acids. 2020 Dec 4; 22: 373–381. - Pubmed link
Hofer, T. et al., Cancers (Basel) 2021 Dec; 13(23): 6107. - Pubmed link
Ramakrishna L. et al., J. Virol., 2004; 78(17): 9174 - 9189 - Pubmed link
Someya K. et al., J. Virol., 2004; 78(18): 9842 - 9853 - Pubmed link
Tsunoda, I. et al., J Virol.,2005; 79(23): 14640-6. - Pubmed link
Yan, L. et al., Infect. Immun.,2008; IAI.00245-08. - Pubmed link
Musson, J. A. et al., Infect. Immun.,2010; (78): 4356-4362 - Pubmed link
Pollard, C. et al., Mol Ther..,2013; 21(1): 251-9 - Pubmed link
Patil, H.P. et al.,Vaccines (Basel). 2017 Jul 27;5(3). pii: E19. - Pubmed link
Van Hoecke L et al., Nat Commun. 2018 Aug 24;9(1):3417 - Pubmed link
Joe, P.T. et al., J Transl Med. 2019 Jul 25;17(1):242. - Pubmed link